Current management of intrahepatic cholangiocarcinoma: from resection to palliative treatments
Categoria dell'articolo: Review
Pubblicato online: 29 lug 2020
Pagine: 263 - 271
Ricevuto: 10 mag 2020
Accettato: 29 giu 2020
DOI: https://doi.org/10.2478/raon-2020-0045
Parole chiave
© 2020 Ilenia Bartolini, Matteo Risaliti, Laura Fortuna, Carlotta Agostini, Maria Novella Ringressi, Antonio Taddei, Paolo Muiesan, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Background
Intrahepatic cholangiocarcinoma (ICC) is the second most common liver primary tumour after hepatocellular carcinoma and represents 20% of all the cholangiocarcinomas. Its incidence is increasing and mortality rates are rising. Surgical resection is the only option to cure the disease, despite the high recurrence rates reported to be up to 80%. Intrahepatic recurrences may be still treated with curative intent in a small percentage of the patients. Unfortunately, due to lack of specific symptoms, most patients are diagnosed in a late stage of disease and often unsuitable for resection. Liver transplantation for ICC is still controversial. After the first published poor results, improving outcomes have been reported in highly selected cases, including locally advanced ICC treated with neoadjuvant chemotherapy, when successful in controlling tumour progression. Thus, liver transplantation should be considered a possible option within study protocols. When surgical management is not possible, palliative treatments include chemotherapy, radiotherapy and loco-regional treatments such as radiofrequency ablation, trans-arterial chemoembolization or radioembolization.
Conclusions
This update on the management of ICC focusses on surgical treatments. Known and potential prognostic factors are highlighted in order to assist in treatment selection.